Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Unwanted effects The fluoroquinolones really are a relatively new number of antibiotics. Fluoroquinolones were first introduced in 1986, but they can also be really modified quinolones, a program of ant
The fluoroquinolones certainly are a group of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, taken from 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the only real orally administered agents readily available for managing serious infections caused by gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have a very wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important aspect in treating community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in youngsters
Newer quinolones produce additional toxicities to the heart which were not found with all the older elements
Fluoroquinolones advantages:
No-fuss administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide variety of both gram-positive and gram-negative bacteria. The latest fluoroquinolones have enhanced activity against gram-positive bacteria with only a small decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is incredibly important because it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, understanding the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were chosen primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing in comparison to the newer quinolones, and they are more susceptible into the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, in addition to some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications inside the remedy for complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones owing to their availability in oral and intravenous formulations and their broad group of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated inside third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.
Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful throughout remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Owing to concern about hepatotoxicity, trovafloxacin therapy ought to be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and also the drug is needed to be taken for not any longer than 14 days.
Negative effects
The fluoroquinolones as a thoughtful class is usually well tolerated. Most adverse reactions are mild in severity, self-limited, and occasionally result in treatment discontinuation. However, they could have serious uncomfortable side effects.
Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the expansion of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones when you are pregnant is not really recommended unless the rewards justify inpending risks to the fetus. These agents may also be excreted in breast milk and will be ignored during breast-feeding if it is possible.
Gastrointestinal effects. The biggest commonplace negative effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness have already been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have already been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones really should be avoided in patients which has a roots or history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms such as dizziness happened in about 50% of the patients.
Phototoxicity. Experience with ultraviolet A rays from directly or indirectly sunlight should really be avoided during treatment and a number of other days (5 days with sparfloxacin) when by using prescription. The degree of phototoxic potential of fluoroquinolones can be as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Be worried about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have been reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be associated with rare liver damage, which prompted the withdrawal of your oral preparations that came from the U.S. market. However, the IV preparation remains an alternative for remedy for infections so serious the fact that benefits outweigh the risks.
Cardiovascular effects. The newer quinolones seem to have been found to produce additional toxicities to your heart have been not found with the older compounds. Evidence advices sparfloxacin and grepafloxacin may have by far the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia are actually reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has long been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the outcome have been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and tend to be mild to moderate in severity, and usually resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important function in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of many fluoroquinolones be 3 -20 hours, providing a few times daily dosing.
Author Resource:-
The fluoroquinolones certainly are a group of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, taken from 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the one orally administered agents an alternative for handling serious infections because of gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important aspect in handling community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in youngsters
Newer quinolones produce additional toxicities towards the heart which are not found with all the older agents
Fluoroquinolones advantages:
Ease in administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a large variety of both gram-positive and gram-negative bacteria. The present fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal reduction in activity against gram-negative bacteria. Their expanded gram-positive activity is incredibly important since it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, comprehending the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were utilized primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing in comparison to the newer quinolones, and they are more susceptible towards the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, along with some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications throughout remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most favored second-generation quinolones because of the availability in oral and intravenous formulations and also their broad range of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated with a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for example Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, they may be less active than ciprofloxacin against Pseudomonas species.
Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful within the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. Additionally they retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Because of concern about hepatotoxicity, trovafloxacin therapy should really be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), along with the drug is needed to be taken for not any longer than 14 days.
Negative effects
The fluoroquinolones as a thoughtful class is usually well tolerated. Most uncomfortable side effects are mild in severity, self-limited, and occasionally result in treatment discontinuation. However, they often have serious negative effects.
Fluoroquinolones are approved for use only in people older than 18. They often affect the increase of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones while pregnant is not recommended unless the rewards justify the potential risks into the fetus. These agents are also excreted in breast milk and should be bypassed during breast-feeding if it is possible.
Gastrointestinal effects. The most common negative effects acquainted with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness seem to have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within three to four days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a tradition of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms similar to dizziness occurred in about 50% of the patients.
Phototoxicity. Skill at ultraviolet A rays from directly or indirectly sunlight really should be avoided during treatment and a few days (5 days with sparfloxacin) as the use of clonazepam. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Bother about the building of musculoskeletal effects, evident in animal studies, has led towards the contraindication of fluoroquinolones for routine use in children as well as in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within weeks time of discontinuation of therapy, spontaneous ruptures have been reported so long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant by using corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be involved with rare liver damage, which prompted the withdrawal of the oral preparations coming from the U.S. market. However, the IV preparation remains intended for treatment of infections so serious that the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to produce additional toxicities to your heart have been not found with all the older compounds. Evidence suggests that sparfloxacin and grepafloxacin could have the foremost cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia continues to be reported with other fluoroquinolones (levofloxacin and moxifloxacin), the outcome are actually mild.
Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a very wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones posses important part in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of your fluoroquinolones range from 3 -20 hours, granting a couple of times daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites